证券代码：600587 证券简称：新华医疗 编号：临 2025-011 山东新华医疗器械股份有限公司 关于 2024 年度利润分配预案和提请股东大会授权董事会制 定 2025 年中期分红方案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中 的任何虚假记载、误导性陈述或者重大遗漏承担连带责任。 重要内容提示： 每股分配比例：山东新华医疗器械股份有限公司（以下简称"公司"或 "新华医疗"）拟向全体股东每 10 股派发现金红利 2.50 元（含税）。不进行资本 公积金转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发 生变动的，公司拟维持现金派发每股分配比例不变，相应调整现金派发总金额， 并将在相关公告中披露。 公司不会触及《上海证券交易所股票上市规则（2024 年 4 月修订）》（以 下简称《股票上市规则》）第 9.8.1 条第一款第（八）项规定的可能被实施其他 风险警示的情形。 一、基本情况 （一）公司 2024 年度利润分配预案 经天职国际会计师事务所（特殊普通合伙）审计，新华医疗 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,307,531,823.28, a decrease of 8.74% compared to ¥2,528,538,840.43 in the same period last year[4]. - Net profit attributable to shareholders was ¥160,455,800.07, down 23.97% from ¥211,036,820.12 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥157,702,901.57, reflecting a decline of 24.53% compared to ¥208,965,933.49 in the previous year[4]. - The basic and diluted earnings per share were both ¥0.27, a decrease of 22.86% from ¥0.35 in the same period last year[4]. - The weighted average return on equity decreased to 2.09%, down 0.78 percentage points from 2.87% year-on-year[4]. - Total operating revenue for Q1 2025 was CNY 2,307,531,823.28, a decrease of 8.7% from CNY 2,528,538,840.43 in Q1 2024[18]. - Net profit for Q1 2025 was CNY 161,227,589.00, a decline of 25.1% compared to CNY 215,024,150.02 in Q1 2024[19]. - Earnings per share for Q1 2025 was CNY 0.27, down from CNY 0.35 in Q1 2024[20]. - The company reported a total comprehensive income of CNY 161,227,589.00 for Q1 2025, compared to CNY 215,024,150.02 in Q1 2024[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥15,324,351,008.59, a decrease of 1.30% from ¥15,526,375,082.77 at the end of the previous year[5]. - The company's current assets totaled CNY 9,059,086,874.27, down from CNY 9,366,020,874.15, indicating a decrease of about 3.3%[14]. - The total liabilities decreased to CNY 6,848,384,341.13 from CNY 7,237,038,074.90, reflecting a reduction of approximately 5.4%[15]. - Total liabilities amounted to CNY 7,155,288,798.36, a decrease from CNY 7,543,748,934.23 in the previous period[16]. - The company's long-term equity investments increased to CNY 1,518,261,716.52 from CNY 1,506,671,275.58, reflecting a growth of about 0.8%[15]. - The total current liabilities amounted to CNY 6,848,384,341.13, which is a significant portion of the total liabilities[15]. Cash Flow - The net cash flow from operating activities was -¥163,624,921.28, an improvement from -¥213,902,750.72 in the same period last year[4]. - Cash received from sales of goods and services in Q1 2025 was CNY 2,039,406,999.49, a slight decrease from CNY 2,070,468,159.18 in Q1 2024[22]. - The net cash flow from operating activities was -$163.62 million, compared to -$213.90 million in the previous period, indicating an improvement of approximately 23.5%[23]. - Total cash inflow from operating activities was $2.11 billion, while cash outflow was $2.28 billion, resulting in a net cash flow of -$163.62 million[23]. - Cash inflow from investment activities was $1.45 million, while cash outflow was $187.67 million, leading to a net cash flow of -$186.21 million[23]. - Cash inflow from financing activities was $455.10 million, with cash outflow totaling $432.62 million, resulting in a net cash flow of $22.48 million[24]. - The total cash and cash equivalents at the end of the period was $2.44 billion, down from $2.65 billion in the previous period[24]. - Payments to employees amounted to $514.46 million, reflecting a decrease from $537.90 million in the previous period[23]. Shareholder Equity - Shareholders' equity attributable to the parent company increased by 2.50% to ¥7,786,792,401.82 from ¥7,597,127,229.99 at the end of the previous year[5]. - Total equity attributable to shareholders increased to CNY 7,786,792,401.82 from CNY 7,597,127,229.99[16]. Operational Insights - The decline in revenue was primarily due to decreased sales in the medical trading segment[8]. - The company reported non-recurring gains of ¥2,752,898.50, after accounting for tax and minority interests[8]. - Research and development expenses increased to CNY 93,857,263.18 in Q1 2025, up from CNY 83,305,119.71 in Q1 2024, reflecting a focus on innovation[19]. - The company reported no significant changes in the shareholder structure or participation in margin financing activities during the reporting period[12]. Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[25].

Financial Performance - The company's operating revenue for 2024 reached RMB 10,020,618,625.09, a slight increase of 0.09% compared to RMB 10,011,868,423.40 in 2023[23] - Net profit attributable to shareholders for 2024 was RMB 691,609,558.03, representing a growth of 5.75% from RMB 653,997,275.95 in 2023[23] - The net profit after deducting non-recurring gains and losses was RMB 623,195,651.23, showing a marginal increase of 0.60% compared to RMB 619,448,862.20 in 2023[23] - Cash flow from operating activities decreased significantly by 56.24% to RMB 450,733,485.54 from RMB 1,030,114,479.17 in 2023[23] - The company's total assets at the end of 2024 were RMB 15,526,375,082.77, a decrease of 0.41% from RMB 15,590,329,775.23 in 2023[23] - The net assets attributable to shareholders increased by 3.81% to RMB 7,597,127,229.99 from RMB 7,318,625,200.44 in 2023[23] - Basic earnings per share for 2024 were RMB 1.14, up 3.64% from RMB 1.10 in 2023[25] - The weighted average return on net assets for 2024 was 9.29%, a decrease of 0.18 percentage points from 9.47% in 2023[25] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares, totaling RMB 151,669,479.75[8] - The cash dividend amount for the year is CNY 151,669,479.75, representing 21.93% of the net profit attributable to ordinary shareholders[155] - The cumulative cash dividend over the last three accounting years is CNY 455,041,722.60, with an average cash dividend ratio of 73.96%[157] Research and Development - The company launched over 100 new products, including key innovations in high-temperature sterilization and 3D imaging technologies[35] - The company has signed 60% more external technology cooperation projects compared to the previous year, enhancing innovation capabilities[36] - The company is recognized as a national key high-tech enterprise and has established multiple provincial-level R&D platforms, contributing to over 100 new key technology innovation projects annually[43] - The company is focusing on upgrading existing products and developing new automated devices, with a registration certificate for fully automated glycosylated hemoglobin equipment obtained in August 2024[47] - The company is committed to technology innovation as a primary driver for growth, emphasizing the importance of talent and innovation in its strategic development[53] Market Expansion and Strategy - The company is expanding its overseas market presence, with successful operations in Indonesia and Saudi Arabia[36] - The company has successfully entered high-end markets such as the EU, achieving its first export sales of multiple products, significantly enhancing its overseas market visibility and share[37] - The company is actively pursuing international market expansion and product certification to enhance its competitive position globally[113] - The company is focusing on market segmentation and precision marketing by conducting in-depth market research and data analysis to tailor marketing strategies based on customer types and consumption habits[112] Operational Efficiency and Cost Management - The company has implemented a VMI inventory management model with core suppliers, effectively reducing internal inventory levels and mitigating supply chain fluctuations[53] - The company has implemented comprehensive cost control measures and optimizing resource allocation to enhance operational efficiency[115] - The company has established partnerships with key industry players to enhance distribution channels and improve market reach[131] Environmental Responsibility - The company invested 1,494,700 CNY in environmental protection during the reporting period[170] - The company has established an environmental management system compliant with GB/T24001-2016 standards to ensure legal and compliant environmental management activities[183] - The company has implemented a clean production approach in its park to promote energy conservation and emission reduction[183] - The company achieved a reduction of 4,776.26 tons in carbon dioxide equivalent emissions through various carbon reduction measures, including a 8.2MW photovoltaic power generation system[184] Corporate Governance - The company ensures compliance with shareholder meeting procedures, safeguarding shareholders' rights and maintaining equal status among all shareholders[122] - The board of directors consists of four independent directors, representing one-third of the board, ensuring the protection of minority shareholders' interests[122] - The company has established various committees, including an audit committee and a remuneration committee, to enhance decision-making processes and reduce risks[122] Legal and Compliance - The company has ongoing litigation with 3M Innovation Co., Ltd. regarding patent infringement, with a settlement amount of RMB 20 million[196] - The company has committed to transparency in its financial disclosures and compliance with relevant regulations[190] - The company has not reported any significant lawsuits or arbitration matters that could materially affect its financial position, aside from the ongoing patent case[195] Employee and Management - The company has a total of 8,135 employees, with 4,132 in the parent company and 4,003 in major subsidiaries[147] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 11.33 million yuan[135] - The management team has a strong background in the medical and financial sectors, enhancing the company's strategic direction[129]

山 东 新 华 医 疗 器 械 股 份 有 限 公 司 募 集 资 金 存 放 与 实 际 使 用 情 况 鉴 证 报 告 天 职 业 字 [2025]12127 号 录 ll 募集资金存放与实际使用情况鉴证报告 ] 关于公司募集资金存放与实际使用情况的专项报告 - 3 您可使用手机"扫一扫"或进入"注册会计师行业统一照管平台（http://acc.mb.geps.cn）"进行查查 您可使用手机"扫一扫"或差入"注册会计师行业统一照管平台（http://accomb.gov.cn）"进行查查 "我们 募集资金存放与实际使用情况鉴证报告 天职业字[2025]12127 号 山东新华医疗器械股份有限公司全体股东: 我们审核了后附的山东新华医疗器械股份有限公司(以下简称"新华医疗")《关于公司募 集资金存放与实际使用情况的专项报告》。 一、管理层的责任 新华医疗管理层的责任是按照中国证监会《上市公司监管指引第2号 -- 上市公司募集资 金管理和使用的监管要求》、上海证券交易所颁布的《上海证券交易所上市公司自律监管指引 第 1 号 -- 规范运作》及相关格式指引规定编制《关于公司募集资金存放与实际使用情况的专 项报告 ...

中信建投证券股份有限公司 关于山东新华医疗器械股份有限公司 2024 年持续督导年度报告书 | 保荐人名称：中信建投证券股份 | 被保荐上市公司名称：山东新华医疗器械股份 | | --- | --- | | 有限公司 | 有限公司 | | 保荐代表人姓名：田斌 | 联系方式：010-56051821 联系地址：北京市朝阳区景辉街 16 号院 1 号楼 | | | 泰康集团大厦 | | 保荐代表人姓名：欧阳志成 | 联系方式：010-56051821 | | | 联系地址：北京市朝阳区景辉街 号院 号楼 16 1 | | | 泰康集团大厦 | 经中国证券监督管理委员会《关于核准山东新华医疗器械股份有限公司非公 开发行股票的批复》（证监许可[2022]1223 号）核准，山东新华医疗器械股份有 限公司（以下简称"新华医疗"）非公开发行人民币普通股（A 股）54,900,098 股，募集资金总额为人民币 1,283,564,291.24 元，扣除各项不含税发行费用人民 币 7,325,377.45 元后，实际募集资金净额为人民币 1,276,238,913.79 元，上述资 金已于 2023 年 2 月 14 日全 ...

中信建投证券股份有限公司 关于山东新华医疗器械股份有限公司 2024 年度日常关联交易和预计 2025 年度日常关联交易 的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券""保荐人"）作为山 东新华医疗器械股份有限公司（以下简称"新华医疗""公司"）非公开发行股票 的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市 规则》《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》等 相关法规和规范性文件的要求，对新华医疗 2024 年度日常关联交易执行情况及 2025 年度日常关联交易预计的事项进行了核查，具体情况如下： 一、日常关联交易基本情况 （一）2024 年日常关联交易的预计和执行情况 单位：万元 | 关联交易类别 | 关联人 | 上年（前次）预 计金额 | 上年（前次）实 际发生金额 | 预计金额与实际发生金 额差异较大的原因 | | --- | --- | --- | --- | --- | | 向 关 联 方 销 售 药 | 山 东 健 康 权 | | | 山东健康正在对下属医 | | 品、器械、设备等 | 属 医 疗 机 构 及子公司 | 21,000. ...

山 东 新 华 医 疗 器 械 股 份 有 限 公 司 审计报告 天 职 业 字 [2025]12133 号 录 审计报告 - l 2024 年度财务报表- -7 2024 年度财务报表附注— -19 您可使用手机"扫一扣"或遗入"注册会计师行业绩"涨食是否由具石频业许师的会计师事务所出具 您可使用手机"扫一扫"或遗入"注册会计师行业统一流管平台（http://ac.mof.gov.cn）"龙行查_ "" 目 审计报告 天职业字[2025]12133 号 山东新华医疗器械股份有限公司全体股东: 一、审计意见 我们审计了山东新华医疗器械股份有限公司(以下简称"新华医疗")财务报表,包括 2024 年 12 月 31 日的合并及母公司资产负债表、2024年度的合并及母公司利润表、合并及母公司现 金流量表、合并及母公司股东权益变动表,以及财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了新 华医疗 2024 年 12 月 31 日的合并及母公司财务状况以及 2024 年度的合并及母公司经营成果和 现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了 ...

中信建投证券股份有限公司 关于山东新华医疗器械股份有限公司非公开发行股票之 2024 年持续督导现场检查报告 上海证券交易所： 中信建投证券股份有限公司（以下简称"保荐人"）作为山东新华医疗器械 股份有限公司（简称"上市公司"、"公司"或"新华医疗"）非公开发行 A 股股 票项目的保荐人，根据《证券发行上市保荐业务管理办法》（以下简称"《保荐办 法》"）以及《上海证券交易所上市公司自律监管指引第 11 号——持续督导》（以 下简称"《持续督导工作指引》"）等相关法规规定，担任本次非公开发行股票项 目持续督导的保荐人，于 2025 年 4 月 1 日和 4 月 28 日对公司进行了现场检查。 现将本次现场检查情况报告如下： 一、本次现场检查的基本情况 核查情况： 保荐人查询了上市公司非公开发行股份上市以来到现场检查之日（简称"持 续督导期"）的股东大会、董事会、监事会及专门委员会的会议文件，并取 1 得了公司章程、股东大会议事规则、董事会议事规则和监事会议事规则、信息披 露制度、内部机构设置及变更等文件，对三会运作情况进行了核查，并对部分董 事、监事、高级管理人员进行了访谈。 核查意见： 上市公司的董事、监事和 ...

山 东 新 华 医 疗 器 械 股 份 有 限 公 司 内 部 控 制 审 计 报 告 天 职 业 字 [2025]12128 号 录 目 内 部 控 制 审 计 报 告 - 您可使用手机"扫一扫"或近入"注册会计师行业统一流管平台（http://ac.cnd.gov.cn）"进行查验。 您可使用手机"扫一扫"或近入"注册会计师行业统一流管平台（http://acc.mc.gov.cn）"进行查验。 l 内部控制审计报告 天职业字[2025]12128 号 山东新华医疗器械股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了山东 新华医疗器械股份有限公司(以下简称"新华医疗")2024年12月31日的财务报告内部控制 的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》的 规定,建立健全和有效实施内部控制,并评价其有效性是新华医疗董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见,并 对注意到的非财务报告内部控制的重大缺陷进行披露。 四、 ...

Core Insights - The medical bed industry in China is experiencing steady growth, with the market size reaching 15.184 billion yuan in 2023 and projected to grow to approximately 17.363 billion yuan in 2024, driven by an aging population and increasing demand for medical services [1][9]. Industry Definition and Classification - Medical beds, also known as healthcare beds, are specialized equipment designed for medical institutions, providing a safe and comfortable platform for patient diagnosis, treatment, care, and rehabilitation [1]. Industry Chain Analysis - The medical bed industry chain consists of four main segments: upstream raw materials and components supply, midstream manufacturing, downstream application services, and supporting industries. The upstream includes suppliers of metals, plastics, and electronic components, while midstream manufacturers produce various types of medical beds. Downstream applications cover hospitals, nursing homes, and home care, with a focus on after-sales services [3]. Development History - The Chinese medical bed industry has evolved over 40 years from reliance on imports to self-innovation. The industry has progressed through several phases: initial reliance on foreign technology, rapid domestic growth driven by healthcare reforms, and the current phase of high-quality development focusing on technology integration and green manufacturing [5]. Current Industry Status - The medical bed market in China is diverse, with ordinary beds holding a significant market share, while multifunctional and electric beds are growing rapidly. The increasing elderly population is expected to drive demand for specialized medical beds [9][12]. Downstream Application Analysis - Hospitals dominate the downstream application of medical beds, accounting for 68% of the market, followed by nursing homes at 18% and home care at 12%. Other institutions, such as rehabilitation centers, make up 2% [12]. Key Enterprises Analysis - The competitive landscape of the medical bed industry is diverse, with companies like Mindray focusing on high-end, intelligent medical beds, while others like Xinhua Medical offer a wide range of products. Companies such as Kofor Medical and Sykon Medical specialize in specific market segments, contributing to a complex competitive environment [14][18]. Future Development Trends - The future of the medical bed industry is expected to focus on high-end technology integration, lightweight materials, and multifunctional designs. High-end beds will incorporate smart sensors and AI for real-time monitoring, while lightweight designs will enhance mobility and comfort. Multifunctional beds will enable various clinical applications, improving efficiency and patient care [20][21][23].